Alvotech: FDA ปิดการตรวจสอบโรงงานในเรคยาวิกด้วยการจัดประเภท VAI

ข้อความจากแหล่งที่มา

Alvotech announces successful closure of FDA inspection of manufacturing facility REYKJAVIK, Iceland, July 29, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has closed its inspection of the company’s manufacturing facility in Reykjavik, Iceland, conducted in May 2026. The FDA has confirmed the inspection classification of the manufacturing site is Voluntary Action Indicated (VAI). “This is an important milestone for Alvotech and reflects the significant work our teams have undertaken to further strengthen our quality systems and manufacturing operations,” said Lisa Grave

ข่าวประชาสัมพันธ์ของบริษัท